EyeCRO are Experts in preclinical efficacy studies in ophthalmic retinopathy, pharmacokinetics, both in vivo and in vitro for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in retina preclinical efficacy, oxygen-induced retinopathy, and ophthalmic pharmacokinetics for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in Laser CNV, Retina preclinical efficacy, and Ophthalmic toxicology for clinical and precise formulation services.

Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research

MiDROPS™

The Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.

In-Vivo

EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Bio Matters: Family influences led EyeCRO’s executive into scientific research

Rafal Farjo, Ph.D. is chief operating officer of both EyeCRO and Charlesson, which are involved in … Read More

Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies

Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins … Read More

EyeCRO co-authors paper in Molecular and Cellular Biology studying mechanisms leading to Diabetic Retinopathy

Serum retinol-binding protein (RBP4) is the sole specific transport protein for retinol in the … Read More

More News

Friday, July 3rd, 2015 at 9:36pm
Biogen Opens Gene Therapy Partnership Worth About $1 Billion http://t.co/DNdbOGGQMf via @business
Tuesday, June 30th, 2015 at 7:58am
Microtubule 'roadway' in the retina helps provide energy for vision -- ScienceDaily http://t.co/JNdZBo6Gu7
Sunday, June 28th, 2015 at 7:37am
Bio Matters: Family influences led EyeCRO’s COO into scientific research http://t.co/TxXldh8ihn
Ophthalmic Contract Research